Literature DB >> 30998618

Effect of Optisol Supplementation With 0.255 μg/mL Amphotericin B on Elimination of Yeast at 5°C.

Devin Tran1, Deepinder Dhaliwal, Roheena Kamyar, Vishal Jhanji, Regis P Kowalski.   

Abstract

PURPOSE: Fungal infections in lamellar keratoplasty are a growing concern. Optisol-GS does not contain an antifungal agent and supplementation with 0.255 μg/mL Amphotericin B (AmpB) has been considered. This study tested the ability of 0.255 μg/mL AmpB in Optisol-GS to eliminate yeast contamination of corneal tissue.
METHODS: Three isolates of Candida albicans, 1 of Candida parapsilosis, and 1 of Candida glabrata were tested in Optisol with and without AmpB. Corneoscleral rims stored at -80°C were thawed and placed in 10 multiwell plates (4 per plate). The rims were inoculated with 4 respective loads of yeast: 0, 10, 10, and 10 colony-forming units in 2 sets of 5 for 5 yeasts. One set was filled with Optisol plus AmpB and the other with Optisol only. All 10 plates were incubated at cold storage (2°C-8°C) for 48 hours. After 48 hours, all corneal rims were placed into 10 mL of yeast extract peptone dextrose medium; a swab culture of each well was plated onto Sabouraud plates; and all plates with the remaining Optisol were incubated at 30°C. Yeast growth was monitored for 10 days. Minimum inhibitory concentration and minimum fungicidal concentration were determined.
RESULTS: All corneoscleral specimens were positive regardless of fungal load or presence of AmpB. All controls remained negative. Minimum inhibitory concentrations and minimum fungicidal concentrations were equivalent and ranged between 0.5 and 2.0 μg/mL.
CONCLUSIONS: AmpB at a concentration of 0.255 μg/mL in Optisol-GS at cold storage (2°C-8°C) over 48 hours did not eliminate yeast from corneal tissue.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30998618     DOI: 10.1097/ICO.0000000000001969

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Efficacy of voriconazole and amphotericin B in corneal preservative media.

Authors:  Sujata Das; Sanchita Mitra; Prashant Garg; Aparajita Mallick; Smruti R Priyadarshini; Savitri Sharma
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

2.  Antifungal Efficacy and Safety of Cycloheximide as a Supplement in Optisol-GS.

Authors:  Melissa Dal Pizzol; Eduarda Correa Freitas; Claudete Locatelli; Felipe Guareze; Paula Reginatto; Gabriella Machado; Alexandre Fuentefria; Diane Marinho
Journal:  Drug Des Devel Ther       Date:  2021-05-18       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.